PHILADELPHIA (June 19, 2019)— Mark Sobczak, MD, FACR, clinical director in the Department of Radiation Oncology at Fox Chase Cancer Center, was selected as a 2019 Fellow of the American College of Radiology (ACR).
PHILADELPHIA (June 19, 2019) — Many of the prediction models used by clinicians to guide patient care and clinical trial selection for solid tumors may not be as accurate as they are thought to be, according to a new study by researchers at Fox Chase Cancer Center.
PHILADELPHIA (June 18, 2019) – Asya Varshavsky-Yanovsky, MD, PhD, will join the faculty as assistant professor in the Hematology and Bone Marrow Transplant Programs within the Department of Hematology/Oncology, on July 1, 2019.
PHILADELPHIA (June 14, 2019) – Researchers at Fox Chase Cancer Center have found that the combined loss of function of three genes commonly associated with pleural malignant mesothelioma – Bap1, Nf2, Cdkn2a – contributed to rapid and aggressive development of the disease in an animal study.
PHILADELPHIA (June 14, 2019) – It has been observed for nearly 300 years that women who have their first child at a young age carry a decreased risk for developing breast cancer throughout their lives. The Irma H. Russo, MD, Breast Cancer Research Lab at Fox Chase Cancer Center, and colleagues have recently demonstrated the biological basis for this naturally protective process.
PHILADELPHIA (June 13, 2019) — Jessica Bauman, MD, an assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, recently received a grant in conjunction with the University of Colorado Denver from the National Institute of Nursing Research.
PHILADELPHIA (June 7, 2019) – Fox Chase Cancer Center has earned CEO Cancer Gold Standard re-accreditation for maintaining a strong commitment to the health of its employees and satisfying the latest comprehensive requirements of the Gold Standard.
PHILADELPHIA (May 23, 2019) — A new combination of established kidney cancer drugs has demonstrated safety and encouraging efficacy in patients with metastatic renal cell carcinoma (mRCC), according to a new clinical trial lead by Matthew Zibelman, MD, on the combination of Axitinib and the PD-1 inhibitor Nivolumab.
